-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

EF Hutton Maintains Buy on Fate Therapeutics, Lowers Price Target to $10

Benzinga · 01/06/2023 07:28
EF Hutton analyst Tony Butler maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and lowers the price target from $16 to $10.